Improving treatment outcome for children with HIV

The Lancet

Volumn 377, Issue 9777, 2011, Pages 1546-1548

  Calmy, Alexandra L ^a,b   Ford, Nathan ^a,c  

^a Médecins Sans Frontires   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; EFAVIRENZ; INTEGRASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; TENOFOVIR;

BODY WEIGHT; CHILD; DRUG FORMULATION; DRUG INDUSTRY; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; NOTE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 79955683351     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60363-2     Document Type: Note

References (13)

1. ML Newell, H Coovadia, M Cortina-Borja, N Rollins, P Gaillard, F Dabis for the Ghent International AIDS Society (IAS) working group on HIV infection in women and children Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis Lancet 364 2004 1236 1243 (Pubitemid 39311344)
2. The PENPACT-1 (PENTA 9/PACTG390) Study Team First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial Lancet Infect Dis 11 2011 273 283
3. PENTA Steering Committee PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection HIV Med 10 2009 591 613
4. A Sohn, J Nuttall, F Zhang Sequencing of antiretroviral therapy in children in low- and middle-income countries Curr Opin HIV AIDS 5 2010 54 60
5. The Pursuing Later Treatment Options (PLATO) II project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Risk of triple-class virological failure in children with HIV: a retrospective cohort study Lancet 2011 10.1016/S0140-6736(11)60208-0 published online April 20.
6. M Davies, M Egger, O Keiser, A Boulle Paediatric antiretroviral treatment programmes in sub-Saharan Africa: a review of published clinical studies Afr J AIDS Res 8 2009 329 338
7. Médecins Sans Frontires Untangling the web of antiretroviral price reduction, 13th edn http://utw.msfaccess.org/background/aids-progress-under- siege 2010 (accessed March 4, 2011).
8. MR Kamya, H Mayanja-Kizza, A Kambugu and Academic Alliance for AIDS Care and Prevention in Africa Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy J Acquir Immune Defic Syndr 46 2007 187 193 (Pubitemid 47482614)
9. MA Davies, H Moultrie, B Eley for the International Epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) Collaboration Virologic failure and second-line antiretroviral therapy in children in South Africa - the IeDEA Southern Africa Collaboration J Acquir Immune Defic Syndr 56 2011 270 278
10. B Waning, E Diedrichsen, E Jambert The global pediatric antiretroviral market: analyses of product availability and utilization reveal challenges for development of pediatric formulations and HIV/AIDS treatment in children BMC Pediatr 10 2010 74 88
11. WHO Priority medicines for mothers and young children http://www.who.int/medicines/publications/A4prioritymedicines.pdf 2011 (accessed April 5, 2011).
12. A Vigano, V Manfredini, F Penagini, V Giacomet, GV Zuccotti Antiretroviral drugs in HIV-infected children Pharmacol Res 2011 10.1016/j.phrs.2011.01.007 published online Jan 19.
13. Drug For Neglected Diseases Initiative http://www.dndi.org (accessed April 5, 2011).